Showing 3421-3430 of 8172 results for "".
Mitomycin C in PRK
https://crstoday.com/crst-issues/apr-2023/mitomycin-c-in-prk/44989/A personal account of the evolution of its use.Retina Update for Anterior Segment Surgeons
https://crstoday.com/crst-issues/feb-2023/retina-update-for-anterior-segment-surgeons/44935/Patient compliance is still a challenge, and OCT is still crucial both before and after cataract surgery.How to Offer CXL Successfully
https://crstoday.com/topics/practice-management/how-to-offer-cxl-successfully/44809/Adopting these technologies and services can boost revenue and help grow your practice.Dropped Nucleus
https://crstoday.com/crst-issues/may-2022/dropped-nucleus-2/44742/Management tips from a retina surgeon.Strategies for Retaining Cataract Surgery Patients
https://crstoday.com/crst-issues/may-2022/strategies-for-retaining-cataract-surgery-patients/44731/Three core principles.Best Practices for Communicating With Confidence and Care
https://crstoday.com/crst-issues/may-2022/best-practices-for-communicating-with-confidence-and-care/44726/Patients with keratoconus are some of the most grateful in my practice.Integrating Imaging & Diagnostics Into EMRs
https://crstoday.com/crst-issues/mar-2021/integrating-imaging-diagnostics-into-emrs/44423/What you need to know.How to Write an Effective Strategic Plan
https://crstoday.com/crst-issues/feb-2021/how-to-write-an-effective-strategic-plan/44413/Get your practice on the road to success by answering these six questions.Say Anything: CRST Readers Share Their Preferences for Refractive Correction and Enhancements After Cataract Surgery
https://crstoday.com/crst-issues/feb-2021/say-anything-crst-readers-share-their-preferences-for-refractive-correction-and-enhancements-after-cataract-surgery/44412/Ocular Surface Disease and Refractive Measurements
https://crstoday.com/topics/cataract-surgery/ocular-surface-disease-and-refractive-measurements/44397/A short preoperative delay so that the corneal surface may be optimized pays dividends in terms of postoperative success.